EUVIMEDEUVIMED entdecken
Open Access

RBM10 loss promotes metastases by aberrant splicing of cytoskeletal and extracellular matrix mRNAs

Gnana P Krishnamoorthy iD, Anthony R Glover iD, Brian R Untch iD, Nickole Sigcha-Coello iD, Bin Xu iD, Dina Vukel iD, Yi Liu iD, Vera Tiedje iD, Jose Mario Bello Pineda iD, Katherine Berman iD, Prasanna P Tamarapu iD, Adrian Acuña-Ruiz iD und 8 weitere

Journal of Experimental Medicine · 2025

DOI: 10.1084/jem.20241029 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Experimental Medicine, 2025. Verfasst von Gnana P Krishnamoorthy und 19 weiteren Autor:innen. Beteiligte Einrichtung: Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Hauptthemen laut MEDLINE: Extracellular Matrix, RNA-Binding Proteins, Cytoskeleton, RNA, Messenger. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NCI NIH HHS, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RBM10 modulates transcriptome-wide cassette exon splicing. Loss-of-function RBM10 mutations are enriched in thyroid cancers with distant metastases. Analysis of transcriptomes and genes mis-spliced by RBM10 loss showed pro-migratory and RHO/RAC signaling signatures. RBM10 loss increases cell velocity. Cytoskeletal and ECM transcripts subject to exon inclusion events included vinculin (VCL), tenascin C (TNC), and CD44. Knockdown of the VCL exon inclusion transcript in RBM10-null cells reduced cell velocity, whereas knockdown of TNC and CD44 exon inclusion isoforms reduced invasiveness. RAC1-GTP levels were increased in RBM10-null cells. Mouse HrasG12V/Rbm1OKO thyrocytes develop metastases that are reversed by RBM10 expression or by combined knockdown of VCL, CD44, and TNC inclusion isoforms. Thus, RBM10 loss generates exon inclusion in transcripts regulating ECM–cytoskeletal interactions, leading to RAC1 activation and metastatic competency. Moreover, a CRISPR-Cas9 screen for synthetic lethality with RBM10 loss identified NFκB effectors as central to viability, providing a therapeutic target for these lethal thyroid cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Extracellular MatrixRNA-Binding ProteinsCytoskeletonRNA, MessengerRNA SplicingAnimalsHumansMiceHyaluronan Receptorsrac1 GTP-Binding ProteinNeoplasm MetastasisTenascinCell Line, TumorVinculinExonsThyroid NeoplasmsGene Expression Regulation, NeoplasticCell MovementAlternative Splicing

Substanzen

RNA-Binding ProteinsHyaluronan Receptorsrac1 GTP-Binding ProteinRNA, MessengerTenascinRBM10 protein, humanVinculin

Autor:innen und Institutionen

  • Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Computational Biology Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

ORCID-Profile: Gnana P Krishnamoorthy, Anthony R Glover, Brian R Untch, Nickole Sigcha-Coello, Bin Xu, Dina Vukel, Yi Liu, Vera Tiedje, Jose Mario Bello Pineda, Katherine Berman, Prasanna P Tamarapu, Adrian Acuña-Ruiz, Mahesh Saqcena, Elisa de Stanchina, Laura Boucai, Ronald A Ghossein, Jeffrey A Knauf, Omar Abdel-Wahab, Robert K Bradley, James A Fagin

Förderung

  • NIH HHS
  • NCI NIH HHS
  • National Health and Medical Research Council
  • Marie-Josée and Henry R. Kravis Center for Molecular Oncology
  • Cycle for Survival
  • Royal Australasian College of Surgeons Foundation
  • National Institutes of Health
  • National Cancer Institute

Zitieren

APA

Krishnamoorthy, G. P., Glover, A. R., Untch, B. R., Sigcha-Coello, N., Xu, B., Vukel, D., Liu, Y., Tiedje, V., Pineda, J. M. B., Berman, K., Tamarapu, P. P., Acuña-Ruiz, A., Saqcena, M., de Stanchina, E., Boucai, L., Ghossein, R. A., Knauf, J. A., Abdel-Wahab, O., Bradley, R. K., & Fagin, J. A. (2025). RBM10 loss promotes metastases by aberrant splicing of cytoskeletal and extracellular matrix mRNAs. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20241029

Vancouver

Krishnamoorthy GP, Glover AR, Untch BR, Sigcha-Coello N, Xu B, Vukel D, et al. RBM10 loss promotes metastases by aberrant splicing of cytoskeletal and extracellular matrix mRNAs. Journal of Experimental Medicine. 2025. doi:10.1084/jem.20241029

BibTeX
@article{Krishnamoorthy2025,
  author = {Krishnamoorthy, Gnana P and Glover, Anthony R and Untch, Brian R and Sigcha-Coello, Nickole and Xu, Bin and Vukel, Dina and Liu, Yi and Tiedje, Vera and Pineda, Jose Mario Bello and Berman, Katherine and Tamarapu, Prasanna P and Acuña-Ruiz, Adrian and Saqcena, Mahesh and de Stanchina, Elisa and Boucai, Laura and Ghossein, Ronald A and Knauf, Jeffrey A and Abdel-Wahab, Omar and Bradley, Robert K and Fagin, James A},
  title = {RBM10 loss promotes metastases by aberrant splicing of cytoskeletal and extracellular matrix mRNAs},
  journal = {Journal of Experimental Medicine},
  year = {2025},
  doi = {10.1084/jem.20241029}
}
Kostenlos starten →